Vera Therapeutics, a late-stage biotech developing therapies for immunological and inflammatory diseases, reported widening net losses in 2025 driven by escalating research and development expenses. Its lead candidate, atacicept, is under FDA review with a decision expected in July 2026, representing a pivotal milestone for the firm’s future. Despite substantial liquidity and a strong current ratio, Vera has no commercial revenues and continues to face typical biotech risks such as clinical setbacks, regulatory uncertainty, and capital needs. The company’s capital allocation remains focused on sustaining clinical programs with no dividends or significant buybacks. Monitoring the FDA’s decision on atacicept and subsequent commercialization readiness will be key to assessing Vera’s trajectory.